Myellama Therapeutics And Vaxcellbio Sign MOU

Myellama Therapeutics has signed a strategic memorandum of understanding with Korean biotechnology company Vaxcellbio to co-develop therapies for multiple myeloma and other indications using its next-generation trispecific engager technology, developed with the National Research Council Canada (NRC).

This agreement establishes a global collaboration among the NRC, the University of Ottawa, Myellama, and Vaxcellbio. ​ Under the MOU, Vaxcellbio and Myellama will jointly evaluate the NRC-developed NK cell engager as a standalone therapy and in combination with Vaxcellbio's allogeneic NK cells for the treatment of multiple myeloma. ​

The partners will assess anti-tumour efficacy and mechanisms of action using patient-derived samples from Korea and Canada in preclinical models. They will also explore advanced delivery technologies, including mRNA-based approaches.

These studies aim to advance the program toward global clinical development and commercialization. ​ The NK cell engager is a next-generation immuno-oncology platform that binds both NK cells and tumour cells, enhancing NK cell recognition and cytotoxic activity against cancer cells. ​

By expanding its global R&D network with leading research institutions and biotechnology partners, Myellama aims to strengthen its technological competitiveness and accelerate the development of innovative immuno-oncology therapies for patients worldwide.

“Natural killer (NK) cells normally eliminate dangerous cells. When focused, they may be used to treat cancer, aging or autoimmune diseases,” states Dr. Brent Zanke, CEO of Myellama. “Collaboration between Vaxcellbio, a world leader in NK cell biology, and Myellama, an immune therapeutics innovator, will advance new NK therapies to extend years and quality of life.”